Pancreatic cancer
Conditions
Interventions
None listed
Sponsors
Japan Oncology Network in Hepatobiliary and Pancreas
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) NAPOLI-1 regimen or S-1 monotherapy is initiated as second-line therapy after failure of gemcitabine=based first-line therapy. 2) Therapy is introduced between September 1, 2019 and February 28, 2021 3) Diagnosis of adenocarcinoma by histological or cytological diagnosis of primary or metastatic lesions. 4) Pancreatic cancer with distant metastasis or recurrent pancreatic cancer by chest CT and abdominal/pelvic contrast-enhanced CT or abdominal/pelvic contrast-enhanced MRI. In the case of recurrent pancreatic cancer, the following items should be followed: a) The first treatment regimen after the diagnosis of recurrence is considered as the primary treatment. b) If postoperative adjuvant chemotherapy was administered, patients are eligible if at least 6 months have elapsed between the last administration of postoperative adjuvant chemotherapy and the recurrence (patients are eligible if the recurrence occurs on the same date 6 months after the last administration of postoperative adjuvant chemotherapy). c) The first treatment regimen after the diagnosis of recurrence is defined as first-line treatment. 5) Patients must not have used irinotecan (including nanoliposomal irinotecan) or fluoropyrimidines. 6) Patients must be at least 20 years of age at the time of enrollment.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival, Objective response rate, Disease control rate | — |
Countries
Japan
Contacts
Public ContactHiroshi Imaoka
National Cancer Center Hospital East Hepatobiliary and Pancreatic Oncology
Outcome results
None listed